- Home
- RCKT vs AUTL Comparison
RCKT vs AUTL Comparison
Compare RCKT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- AUTL
- Stock Information
- Founded
- RCKT 1999
- AUTL 2014
- Country
- RCKT United States
- AUTL United Kingdom
- Employees
- RCKT N/A
- AUTL N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCKT Health Care
- AUTL Health Care
- Exchange
- RCKT Nasdaq
- AUTL Nasdaq
- Market Cap
- RCKT 1.4B
- AUTL 1.1B
- IPO Year
- RCKT N/A
- AUTL 2018
- Fundamental
- Price
- RCKT $13.98
- AUTL $3.08
- Analyst Decision
- RCKT Strong Buy
- AUTL Strong Buy
- Analyst Count
- RCKT 9
- AUTL 2
- Target Price
- RCKT $53.22
- AUTL $11.50
- AVG Volume (30 Days)
- RCKT 744.0K
- AUTL 2.3M
- Earning Date
- RCKT 11-07-2024
- AUTL 11-12-2024
- Dividend Yield
- RCKT N/A
- AUTL N/A
- EPS Growth
- RCKT N/A
- AUTL N/A
- EPS
- RCKT N/A
- AUTL N/A
- Revenue
- RCKT N/A
- AUTL $10,091,000.00
- Revenue This Year
- RCKT N/A
- AUTL $816.67
- Revenue Next Year
- RCKT $411.05
- AUTL $374.47
- P/E Ratio
- RCKT N/A
- AUTL N/A
- Revenue Growth
- RCKT N/A
- AUTL 82.71
- 52 Week Low
- RCKT $13.80
- AUTL $2.94
- 52 Week High
- RCKT $32.53
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- RCKT 27.71
- AUTL 35.72
- Support Level
- RCKT $16.65
- AUTL $3.24
- Resistance Level
- RCKT $17.83
- AUTL $4.12
- Average True Range (ATR)
- RCKT 0.89
- AUTL 0.37
- MACD
- RCKT -0.27
- AUTL -0.09
- Stochastic Oscillator
- RCKT 4.12
- AUTL 8.48
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.